What is the half-life of IGF-1 LR3?

IGF-1 LR3 has a half-life of 20-30 hours, which is why it's typically administered Once daily, often mail-workout on training days for optimal therapeutic effect.

How do I reconstitute IGF-1 LR3?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Muscle Growth

Preclinical

IGF-1 LR3

Also known as: Long R3 IGF-1, LR3-IGF-1, IGF-1 Long R3

Overview

Key Facts

Primary Goal: A modified analog of human IGF-1 featuring an arginine substitution at position 3 and a 13-amino-acid N-terminal extension

A modified analog of human IGF-1 featuring an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications drastically reduce binding to IGF binding proteins (IGFBPs), resulting in a much longer effective half-life and greater bioavailability than native IGF-1. It is one of the most potent peptides for promoting skeletal muscle hypertrophy and hyperplasia. Half-Life 20-30 hours Typical Dose 20–100 mcg Frequency Once daily, often mail-workout on training days Cycle Length 4-6 weeks on, 2-4 weeks off

Dosing Information

Half-Life

20-30 hours

Typical Dose

20–100 mcg

Frequency

Once daily, often post-workout on training days

Cycle Length

4-6 weeks on, 2-4 weeks off

Administration Routes:

subcutaneousintramuscular

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Preclinical

IGF-1 LR3 has been widely studied in cell culture and animal models, demonstrating potent anabolic effects. Studies show 2-3x greater potency than native IGF-1 in stimulating muscle protein synthesis due to reduced IGFBP sequestration. Research in livestock has shown significant increases in lean mass. While no formal clinical trials exist for the LR3 variant, native IGF-1 (mecasermin) is FDA-approved for growth failure, establishing the pathway's clinical validity.